Federal Judge Temporarily Upholds Access to Abortion Medication

On Tuesday, Federal Judge David C. Joseph ruled that the abortion pill mifepristone stays available across the US while the FDA continues to review its safety among patients, according to NPR.¹ As Joseph wrote in his ruling, it was his opinion that the FDA should control and decide on access to mifepristone rather than the courts, leaving it up to the administration’s safety review, which will be updated in about 6 months.

“We're seeing a kind of civil war between Republicans about how quickly and how far to go that the Louisiana case exemplifies,” Mary Ziegler, JD, legal history professor at the University of California, Davis, said to NPR. “Abortion opponents [are] trying to force the president and Congress into more of an absolute stand instead of letting them fudge their position as they have, to some degree, to date.”

Joseph granted a stay in a case brought by the state of Louisiana, allowing the FDA to proceed with its own ongoing safety review of the medication. Although the 37-page ruling expressed some sympathy for the state’s arguments regarding the alleged harms of mail-order medication, the judge ultimately deferred to the FDA’s scientific expertise to evaluate public health evidence.^1,2

The court has ordered the agency to provide an update on its progress within 6 months, warning that this pause is not indefinite.

READ MORE: Senator Introduces Legislation to Remove FDA Approval of Mifepristone

This legal reprieve is particularly significant for the pharmacy profession, which has seen its role in reproductive health care expand rapidly in recent years. In early 2023, the FDA modified its Risk Evaluation and Mitigation Strategy (REMS) program to allow certified retail pharmacies to dispense mifepristone directly to patients.^3,4

This regulatory shift, alongside the removal of in-person dispensing requirements during the pandemic, has fueled a surge in telehealth abortions, which now account for more than 25% of terminations in the US. For many practitioners, this has meant integrating a complex certification process, ensuring shipment tracking, and managing the clinical contraindications of a drug that is now used in approximately 63% of all US abortions.^1-4

Hawley and Co’s Fight to Ban Medication Abortion

Despite the drug's widespread use and 20-plus-year history of approval, it remains under intense legislative and judicial fire.

Senator Josh Hawley (R, Missouri) recently introduced the Safeguarding Women from Chemical Abortion Act—a bill that seeks to permanently revoke the FDA’s approval of mifepristone for terminating pregnancies. Hawley and other Republican supporters argue that the drug is inherently dangerous, citing disputed data claiming serious health effects in 11% of cases.^4,5

Interestingly, the proposed legislation would still allow the medication to be prescribed for Cushing syndrome under different product branding, a nuance that would force pharmacists to manage the same chemical entity under divergent legal frameworks based on its indicated use.⁴

The political push to restrict the drug stands in sharp contrast to emerging scientific trends. A recent study published in JAMA Internal Medicine explored the possibility OTC medication abortion, using a prototype kit named “MiMi” to test patient self-assessment, according to a separate NPR report.⁶

The researchers found that 88% of participants could accurately determine their own eligibility for the medication, suggesting that the drugs meet safety criteria for an OTC switch. Furthermore, a comprehensive analysis by Johns Hopkins Bloomberg School of Public Health of over 5000 pages of internal FDA documents concluded that the administration’s regulation of mifepristone has been consistently shaped by evidence and caution rather than ideological bias.^4,6

The Pharmacist’s Place Amid Mifepristone Debates

As the legal battle continues, pharmacists find themselves at the intersection of conflicting state and federal mandates. Although some states have passed shield laws to protect providers, others, like Louisiana, have taken the unprecedented step of scheduling mifepristone as a controlled substance and pursuing criminal charges against out-of-state health care professionals.^1,2,6

For the approximately 1 in 4 women who will have an abortion in their lifetime, these legal shifts determine whether they can access a safe medication at a median cost of $568 or must overcome significant economic and logistical barriers. With the FDA’s review pending, the pharmaceutical landscape for reproductive health remains in a state of high-stakes evolution.^3,4,6

“This attack on mifepristone will bring Senator Josh Hawley one step closer to his ultimate goal: ending access to abortion for everyone, everywhere,” wrote the Planned Parenthood Action Fund in a recent statement.⁷ “This is yet another effort from abortion opponents to restrict access to care and spread even more misinformation about a safe and effective medication that millions of people have used. Planned Parenthood Action Fund will never stop fighting for everyone’s right to get the care they need, when and where they need it.”

READ MORE: Women’s Health Resource Center

Don’t get left behind: Sign up today for our free Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips delivered straight to your inbox.

REFERENCES

1. Simmons-Duffin S. Telehealth abortion will remain available for now, after a federal judge’s ruling. NPR. April 7, 2026. Accessed April 9, 2026. https://www.npr.org/2026/04/07/nx-s1-5776946/telehealth-abortion-louisiana-federal-court-mifepristone

2. Judge refuses to block sending abortion pill by mail for now, but says FDA must finish review. CNN Health. April 8, 2026. Accessed April 9, 2026. https://www.cnn.com/2026/04/08/health/abortion-pill-mifepristone-by-mail

3. Sawhill IV, Smith K. Abortion in the US: what you need to know. The Brookings Institution. May 29, 2024. Accessed April 9, 2026. https://www.brookings.edu/articles/abortion-in-the-us-what-you-need-to-know/

4. Nowosielski B. Senator introduces legislation to remove FDA approval of mifepristone. Drug Topics. March 12, 2026. Accessed April 9, 2026. https://www.drugtopics.com/view/senator-introduces-legislation-to-remove-fda-approval-of-mifepristone

5. Bolton A. Hawley bill to end FDA approval mifepristone picks up Senate GOP support. The Hill. March 25, 2026. Accessed April 9, 2026. https://thehill.com/homenews/senate/5800153-gop-support-hawley-mifepristone-bill/

6. Simmons-Duffin S. Over-the-counter medication abortion? These researchers say it would be safe. NPR. April 6, 2026. Accessed April 9, 2026. https://www.npr.org/2026/04/06/nx-s1-5773372/medication-abortion-jama-safety-mifepristone-misoprostol

7. Planned Parenthood Action Fund statement on legislation to effectively ban mifepristone. News Release. Planned Parenthood Action Fund. March 11, 2026. Accessed April 9, 2026. https://www.plannedparenthoodaction.org/pressroom/planned-parenthood-action-fund-statement-on-legislation-to-effectively-ban-mifepristone